Cited by 584Psychedelics and Drug StudiesSubstance Abuse Treatment and OutcomesNeurotransmitter Receptor Influence on Behavior

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials

Krebs, Teri S, Johansen, Pål-Ørjan·2012·Journal of Psychopharmacology

DOI 10.1177/0269881112439253

Open this paper in CoChat — free account

Abstract

Assessments of lysergic acid diethylamide (LSD) in the treatment of alcoholism have not been based on quantitative meta-analysis. Hence, we performed a meta-analysis of randomized controlled trials in order to evaluate the clinical efficacy of LSD in the treatment of alcoholism. Two reviewers independently extracted the data, pooling the effects using odds ratios (ORs) by a generic inverse variance, random effects model. We identified six eligible trials, including 536 participants. There was evidence for a beneficial effect of LSD on alcohol misuse (OR, 1.96; 95% CI, 1.36–2.84; p = 0.0003). Between-trial heterogeneity for the treatment effects was negligible (I 2 = 0%). Secondary outcomes, risk of bias and limitations are discussed. A single dose of LSD, in the context of various alcoholism treatment programs, is associated with a decrease in alcohol misuse.

Integrity signals

Registry

Crossref · 10.1177/0269881112439253

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders
Rehm, J., Mathers, C., Popova, S., Thavorncharoensap, M., Teerawattananon, Y., & Patra, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60746-7 · Cited by 3,870
Untitled work
(2008) · Cited by 3,790
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 2×
“, 2002; McGlothlin, 1964), and in clinical studies the effects of psychedelics are often regarded as highly valued and meaningful (Griffiths et al., 2006; Grob et al., 2011; Studerus et al., 2011).”
Background
Drug harms in the UK: a multicriteria decision analysis
Nutt, D. J., King, L. A., & Phillips, L. D. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61462-6 · Cited by 1,681
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206
Human hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203
Opioid antagonists for alcohol dependence
Srisurapanont, M., & Jarusuraisin, N. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001867 · Cited by 762
Alcohol-use disorders
Schuckit, M. A. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60009-x · Cited by 715
Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies
Studerus, E., Kometer, M., Hasler, F., & Vollenweider, F. X. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110382466 · Cited by 532 · cited 2×
“, 2002; McGlothlin, 1964), and in clinical studies the effects of psychedelics are often regarded as highly valued and meaningful (Griffiths et al., 2006; Grob et al., 2011; Studerus et al., 2011).”
Background
The pharmacology of lysergic acid diethylamide: A review
Passie, T., Halpern, J. H., Stichtenoth, D. O., Emrich, H. M., & Hintzen, A. (2008) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2008.00059.x · Cited by 455

Show all 39 references

Research works printed but not linked: 6

Ables MF, 1967, Highlights of the twelfth annual conference in cooperative studies in psychiatry
Ables MF, 1970, Group treatment of chronic alcoholism with LSD-25: study II. Newsletter for research in psychology, United States Veterans Administration, 12, 17
American Psychiatric Association (1952) Diagnostic and Statistical Manual for Mental Disorders. First Edition. Washington, DC: American Psychiatric Association, 39.
Kurland AA, 1971, Advances in neuropsychopharmacology: proceedings of the 7th congress of the collegium internationale neuro-psychopharmacologicum, 361
Rösner S, 2010, Cochrane Database Syst Rev, 9, CD004332
Rösner S, 2010, Cochrane Database Syst Rev, 12, CD001867

Sorted by citations

Items 501–584 of 584

New insights into the clinical and nonclinical effects of psychedelic substances: an integrative reviewPreprint
Forstmann, M., & Sagioglou, C. (2021) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/2489x
Clinical Applications
Yaden, D. B., & Newberg, A. B. (2022) · doi:10.1093/oso/9780190665678.003.0018
Estigmas do tratamento com LSD: um estudo exploratório
Furini, V. C., & Cecconello, W. W. (2022) · Revista Pesquisa Qualitativa · doi:10.33361/rpq.2022.v.10.n.24.505
A Question of Dose and Context: LSD, Peyote and Chemical Interactions, Human Variation, and Interpretation
Caldararo, N. (2022) · Springer eBooks · doi:10.1007/978-3-031-13745-7_2
BAPI
(2023) · Boletim de Análise Político-Institucional · doi:10.38116/bapi33
Aplicações terapêuticas e benéficas do LSD: uma revisão sistemática
Marson, M. A. G., Neto, J. V. D. P., Zaniratto, J., & Borges, K. K. (2023) · Peer Review · doi:10.53660/516.prw1503b
Experiencias psicodélicas: fenomenología, potenciales terapéuticos y modelos explicativos
Chernoff, T., Kliger, B., & Venturini, D. H. (2023) · Vertex Revista Argentina de Psiquiatría · doi:10.53680/vertex.v34i160.463
Classical psychedelics in psychiatry – renaissance of interest and therapeutic perspectives
Jachimowski, A., & Kucia, K. A. (2023) · Psychiatria Polska · doi:10.12740/pp/150053
Psilocybin Use in Palliative Care #464
Sims, M. D., & Hendrick, J. (2023) · Journal of Palliative Medicine · doi:10.1089/jpm.2023.0180
The Use of Illicit Drugs in Therapy: an Introduction
Ross, A., & Hawthorn, J. (2023) · Current Addiction Reports · doi:10.1007/s40429-023-00509-z
O Uso da ibogaína no manejo da dependência de drogas no Brasil
Gomes, B. R. (2021) · doi:10.47749/t/unicamp.2021.1245563
Entre a lei e a sentença
Medeiros, D. G. D. M. D. S. (2022) · doi:10.47749/t/unicamp.2022.1259324
Farmakológiai biopolitikák (1. rész) : A lélek vegyészete
Básthy, Á., & Lengyel, Z. (2023) · Replika · doi:10.32564/129.1
A history and future of psychedelics: The case of the Canadian military
Dyck, E., & Marchildon, G. P. (2023) · Journal of Military Veteran and Family Health · doi:10.3138/jmvfh-2023-0010
Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder: Protocol for a Double-Blind, Randomized, Placebo-Controlled, 7-month Parallel-Group Phase II Superiority TrialPreprint
Vanderijst, L., Hever, F., Buot, A., Dauré, C., Benoit, J., Hanak, C., Veeser, J., Morgiève, M., Campanella, S., Kornreich, C., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-3829237/v1
Traitements psychédéliques et soins en addictologie
Dauré, C., & Mallet, L. (2023) · Elsevier eBooks · doi:10.1016/b978-2-294-77934-3.00069-x
Exploring inner depths
Breeksema, J. J. (2024) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.912040905
Introduction to the EMBARK Approach
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.003.0003
Preparation Sessions
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.003.0006
Bringing It Home and Carrying It Forward
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.003.0009
Considerations Prior to Meeting With a Participant
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.003.0005
INTRODUCTION: A New Approach for the Whole Person
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.003.0001
Choosing Suggested Integration Goals
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.005.0004
Working Within the EMBARK Domains Cheat Sheet
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.005.0003
Medicine Sessions
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.003.0007
Therapist Aims Cheat Sheet
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.005.0002
An Overview of Psychedelic-Assisted Therapy
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.003.0002
Personal Care for the Therapist
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.005.0001
Integration Sessions
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.003.0008
Authors’ Note
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.002.0004
EMBARK Mechanisms of Change in the Treatment of Depression
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.003.0004
Medical Use of Cannabinoids and Psychedelic Compounds
Inserra, A., Gregorio, D. D., & Gobbi, G. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_141-2
Psilocybin in the Management of Substance Use Disorders: A Summary of Current Evidence
Bourji, H. E., Farhat, A., Hamdan, Z., Satodiya, R. M., Shukla, R., & Hayek, S. E. (2024) · Current Psychopharmacologye · doi:10.2174/0122115560288779240628043307
Psilocybin and other Psychedelics
Kaye, A. P., Kelmendi, B., Rivera, M. N., & Pittenger, C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95702-1.00178-0
Medical Use of Cannabinoids and Psychedelic Compounds
Inserra, A., Gregorio, D. D., & Gobbi, G. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_141
Public Health and the Harm Reduction Approach to Illegal Psychoactive Substances
Emerson, B., & Haden, M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-99967-0.00380-x
The Future of Alcohol Use Disorder Treatment and Research
Srivastava, A. B., & Wai, J. M. (2024) · Psychiatry update · doi:10.1007/978-3-031-73553-0_15
Pharmacotherapies for Alcohol Use Disorder
Makovkina, E. (2024) · Psychiatry update · doi:10.1007/978-3-031-73553-0_7
Alkohol
(2024) · Elsevier eBooks · doi:10.1016/b978-3-437-21074-7.00010-1
Innovative pharmakologische Ansätze zur Behandlung von Suchterkrankungen
Mick, I., Müller, C. A., & Majić, T. (2024) · Elsevier eBooks · doi:10.1016/b978-3-437-21074-7.00008-3
Psychedelics for Substance Use Disorders: Updates for the Psychiatric Trainee
Wilseck, L., Chatha, P., Canale, L., Raval, D., & Weleff, J. (2025) · American Journal of Psychiatry Residents Journal · doi:10.1176/appi.ajp-rj.2025.200301
Views on Psychedelic-Assisted Therapy for Substance Use Disorders from Individuals with Opioid Use Disorder and a History of Injection-Related Infections: A Qualitative Study
Szpak, V., Maddams, S., Kim, A., Sager, Z. S., & Suzuki, J. (2025) · Psychedelic Medicine · doi:10.1089/psymed.2025.0003
Evaluating the Effectiveness of Psychedelic-Assisted Therapy in Treating Alcohol Use Disorders: A Review
Shah, R. J., & Sarangi, A. (2025) · Alcoholism Treatment Quarterly · doi:10.1080/07347324.2025.2500345
LSD
Lerner, Z. I., Liu, J. C., Thielking, P. D., & Luce, D. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780197760864.003.0004
« Trip » sous LSD : le psychédélisme des sixties
Robert, F. (2025) · Drogues santé et société · doi:10.7202/1118068ar
Stability-Guided Formulation of a Light-Sensitive D-LSD Capsule for Clinical Investigation
Do, B., Mallet, L., Annereau, M., Libong, D., Solgadi, A., Vorspan, F., Paul, M., & Secrétan, P.-H. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17060767
LSD Restores Synaptic Plasticity in VTA of Morphine-Treated Mice and Disrupts Morphine-Conditioned Place PreferencePreprint
Gunten, M. V., Russell, T., Stirland, I., Parks, S., Jenkins, T. G., & Edwards, J. G. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.12.658958
Prolegomena to a Phenomenology of Psychedelic Experiences
Forde, D. (2025) · New Directions in Philosophy and Cognitive Science · doi:10.1007/978-3-031-95203-6_1
Mécanismes d’action et perspectives thérapeutiques du LSD : état des lieux actuel
Bouloufa, A., Delcourte, S., & Haddjeri, N. (2025) · Biologie Aujourd hui · doi:10.1051/jbio/2025008
Psychedelics for the Treatment of Substance Use Disorders: A Narrative Review of the Literature
Marcus, O., & Rush, B. R. (2025) · Substance Use & Addiction Journal · doi:10.1177/29767342251351123
Reluctant risk-takers: how law enforcement practices at festivals can obstruct safer drug use
Ruane, D. (2025) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2025.105013
Efficacy and Safety of Psychoactive Tryptamines in Addiction: A Systematic Review
van der Meer, P. B., Schukking, N., Dik, M., van Reemst, A., Fuentes, J. J., Kaptein, A. A., Schoones, J. W., Verboeket, S. O., de Waal, M. M., Goudriaan, A. E., et al. (2025) · Psychedelic Medicine · doi:10.1177/28314425251364182
The Relationship Between Psychedelic Use and Alcohol Use Disorder in a Nationally Representative Sample
Zech, J. M., Richard, J., & Jones, G. M. (2025) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2025.2583967
Interactions between psilocybin, LSD, and serotonergic antidepressants: A qualitative analysis of user reports
Hepburn, H., Ellenbroek, B. A., & Youn, J. (2025) · Psychedelics · doi:10.1016/j.psyche.2025.100005
The Potential Therapeutic Effects of MEAI in the Treatment of Alcohol Use Disorder
Ekhlasi, M., Frytz, A., & Nia, A. B. (2025) · Current Addiction Reports · doi:10.1007/s40429-025-00700-4
Chapter 8. Hallucinogens and Phencyclidine
DeVido, J. J., & Epson, M. F. (2025) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9798894550862.lg08
Chapter 11. Integrative Medicine Approaches to Addiction Treatment
Yerramsetti, S. M., Marienfeld, C. B., & DeVido, J. J. (2025) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9798894550862.lg11
Positionspapier zu Psychedelika assistierter Therapie von Abhängigkeitserkrankungen der Schweizerischen Gesellschaft für Suchttherapie
Wopfner, A., Beck, T., & Penzenstadler, L. E. (2025) · SUCHT - Zeitschrift für Wissenschaft und Praxis / Journal of Addiction Research and Practice · doi:10.1024/0939-5911/a000954
Measuring Altered States of Consciousness in Virtual Reality: A Systematic Analysis of Assessment Methods
Mele, M. L., & Rutrecht, H. M. (2026) · Lecture notes in computer science · doi:10.1007/978-3-032-12808-9_8
Contextualizing Violence Risk Associated With Hallucinogens
Durns, T. A., & Iannuzzi, G. (2026) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20250027
These aren’t the beliefs you’re looking for: on the limits of affect-neutral accounts of psychedelic therapy
Blaise, C. R. (2026) · Synthese · doi:10.1007/s11229-026-05443-x
THE PSYCHEDELIC RENAISSANCE: A SYSTEMATIC REVIEW OF PSILOCYBIN AND LSD IN THE TREATMENT OF PSYCHIATRIC DISORDERS
Klepacz, J., Swędrak, R., Swojnóg, M., & Dobrakowska, Z. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.1(49).2026.4582
Le LSD revisité : mécanismes d’action et potentiel en santé mentale
Bouloufa, A., Delcourte, S., Delannay, T., & Haddjeri, N. (2026) · L Encéphale · doi:10.1016/j.encep.2026.02.008
Exploring new avenues: Psychedelic‐assisted therapy for young people
Vamvakopoulou, I. A., Nicholls, D., Nutt, D. J., & Simplicio, M. D. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70579
Depressions- und Angstsymptome nach psychedelisch-assistierter Psychotherapie bei therapieresistenter Depression: retrospektive Routinedatenanalyse mit vs. ohne komorbide Substanzkonsumstörung
Penzenstadler, L. E., Brakha, T. A., & ZULLINO, D. F. (2026) · Suchttherapie · doi:10.1055/a-2599-1389
Lysergic acid diethylamide pretreatment prolongs brain-stimulation induced neural activity changes
Dwiel, L. L., Prina, M. L., Bragg, E. M., Drucker, L. L., Reduron, L. R., Luikart, B. W., & Doucette, W. T. (2026) · Brain stimulation · doi:10.1016/j.brs.2026.103130
A trip through the psychiatric use of psychedelics in Brazil: A scoping review
Kami, V. R., Salle, B. B. B., Porto, G., Cavalari, V. C., & Roza, T. H. (2026) · Psychedelics · doi:10.1016/j.psyche.2026.100024
Attitudes and perceptions of psychedelic therapy among clinical trial participants with alcohol use disorder: a mixed-method study
Kirsch, J., Poppe, C. J., Beck, A., Brabeck, A., Gutwinski, S., Lütt, A., Rosenthal, A., Tsamitros, N., & Repantis, D. (2026) · Psychopharmacology · doi:10.1007/s00213-026-07104-w
THE PSYCHEDELIC AND KETAMINE RENAISSANCE IN THE FACE OF THE CRISIS IN MODERN PSYCHIATRY
Osipowska, J., Kwolek, M., Judzińska, A., Piech, B., Sobczyńska, K., Ignarska, J., Terbosh, M., `Mzabi, S. K., Trojanowska, E., & Dubaj, M. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5605
Decoding the serotonin–alcohol crosstalk: the role of central serotonergic dysregulation in alcohol use disorder
Zaniewska, M. (2026) · Pharmacological Reports · doi:10.1007/s43440-026-00860-8
Single Ayahuasca administration attenuates alcohol relapse and associated behavioral, neurochemical, and oxidative alterations in rats
Lodetti, G., de Bitencourt, R. M., Inserra, A., Redivo, H., Teixeira, A. G., de Farias, A. C. S., Pickler, K. D. P., Rohling, J. P. V., Endler, A. T., Zampronio, E. P., et al. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111817
Psychedelics, rebirth experiences, and the limits of current research
Artru, E. (2026) · Psychedelics · doi:10.1016/j.psyche.2026.100028
What About Psycholytic Therapy? A Historical Revisiting of Psychedelics Assisting Psychotherapy
Zaher, I., & Richard, J. (2026) · Psychedelic Medicine · doi:10.1177/28314425261455416
Psychedelics and Reward Processing: Before and After the 1970 Controlled Substances Act
Lifshitz, D. J., Sawaya, M. F., & Murnane, K. S. (2026) · Psychedelic Medicine · doi:10.1177/28314425261472614
Psychological change processes in alcohol use disorder: A qualitative study of 5‐methoxy‐ N , N ‐dimethyltryptamine (5‐MeO‐DMT) with cognitive behavioural therapy
Seynaeve, M., Dunbar, F., Ermakova, A. O., Mitcheson, L., Rucker, J., Cleare, A. J., & Marsden, J. (2026) · Addiction · doi:10.1111/add.70555
Substanzgebrauchsstörungen
Rohrmoser, B., & Koslowski, M. (2026) · Elsevier eBooks · doi:10.1016/b978-3-437-21293-2.00014-9
Klassische Halluzinogene in der Behandlung von Suchterkrankungen – Ein narrativer Überblick
Kippe, Y. D., Poppe, C. J., Repantis, D., & Majić, T. (2026) · Suchttherapie · doi:10.1055/a-2596-8400
Transpersonal Psychotherapies
Wade, J., Alongi, P., & Hermida, J. (2026) · Wiley eBooks · doi:10.1002/9781394215683.ch30
Through the Looking-Glass: A Scoping Review of Psychological Mechanisms of Psychedelic-Assisted Therapy for Substance Use Disorders
Fletcher, K., Freestone, J., Ezard, N., Knock, E., & Siefried, K. J. (2026) · Current Addiction Reports · doi:10.1007/s40429-026-00783-7
Justice Involvement and Hallucinogen Use Among US Adults: Exploring Health Problems, Other Substance Use, and Demographic Correlates
Karaaslan, F. G., Philippon, C., & Ford, J. A. (2026) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2026.2727014
Psychedelic therapy without durable effects: A review and re-evaluation of controlled studies between 1965 and 1977
Passie, T., & van Elk, M. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261478606
Perceptions and experiences of psychedelic substance use: a qualitative thematic analysis of Polish-language Reddit posts
Jankowska, E., & Świeczkowski, D. (2026) · Drugs Education Prevention and Policy · doi:10.1080/09687637.2026.2729740
MDMA administration reduces ethanol drinking and is associated with altered nociceptin and dynorphin system gene expression in alcohol-preferring rats
Rullo, L., Losapio, L. M., Mrizak, H., Morosini, C., Nasuti, C., Ubaldi, M., Mangione, P., Lacorte, A., Coluzzi, F., Soverchia, L., et al. (2026) · Neuropharmacology · doi:10.1016/j.neuropharm.2026.111187
Efficacy and safety of psilocybin-assisted therapy for alcohol use disorder: A systematic review and meta-analysis
Florineth, G. A., Boeker, A. L., Bracht, T., Wopfner, A., Denier, N., Adorjan, K., Müller, F., & Soravia, L. M. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261490221

Authors: Krebs, T. S., & Johansen, P.-Ø.
Affiliations: Harvard University (US)
Venue: Journal of Psychopharmacology
Publisher: SAGE Publications
Published: 2012-03-08
Volume: 26
Issue: 7
Pages: 994-1002
ISSN: 0269-8811 (ISSN-L)
1461-7285
DOI: 10.1177/0269881112439253
OpenAlex: W1973613743
Cited by: 583
References: 39
Citations by year: 2026: 39 · 2025: 55 · 2024: 67 · 2023: 63 · 2022: 59 · 2021: 52 · 2020: 55 · 2019: 25 · 2018: 34 · 2017: 29 · 2016: 31 · 2015: 25 · 2014: 23 · 2013: 19 · 2012: 6
FWCI: 3.40
Type: journal article
Language: en
Open access: closed
Licence: journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations: Journal of Psychopharmacology (publishedVersion)
PubMed (publishedVersion)
Topics: Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords: lysergic acid diethylamide, LSD, alcoholism, alcohol abuse, psychedelic therapy, alcoholism treatment, treatment efficacy
MeSH terms: Adult, Alcoholism, Combined Modality Therapy, Hallucinogens, Humans, Lysergic Acid Diethylamide, Randomized Controlled Trials as Topic, Substance Abuse Treatment Centers, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks